CRSP Stock Analysis: Buy, Sell, or Hold?
CRSP - CRISPR Therapeutics AG
$45.75
-1.80 (-3.79%)
▼
5d:
-1.06%
30d:
-25.9%
90d:
-18.54%
HOLD
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 05, 2026
Smart Money Accumulation
CRSP is down 7.3% this week, but smart money is accumulating calls. Top strike: $60 2026-06-18 with 783 OI. Call ratio: 63% View Scanner →
Strength: 4.9/10
Get Alerted When CRSP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CRSP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CRSP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CRSP is currently trading at $45.75, which is considered oversold relative to its 30-day fair value range of $47.66 to $57.69.
Technical Outlook: Technically, CRSP is in a strong uptrend. The price is currently testing key support at $45.12. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: CRSP has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $83.35 (+82.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CRSP is in a strong uptrend. The price is currently testing key support at $45.12. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: CRSP has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $83.35 (+82.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$47.66 -
$57.69
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
Protect Your Profits
Holding CRSP? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.8%)
- BULLISH: Trading 82.2% below Wall St target ($83.35)
Fair Price Analysis
30-Day Fair Range
$47.66 -
$57.69
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$45.12
Resistance Level
$50.19
Current Trend
Strong Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.92
Wall Street Target
$83.35
(+82.2%)
Revenue Growth (YoY)
-97.6%
Share & Embed Analysis
Last updated: March 30, 2026 7:06 AM ET
Data refreshes hourly during market hours. Next update: 8:06 AM
Data refreshes hourly during market hours. Next update: 8:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRSP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
James R Kasinger
SELL
3450 shares
2026-03-16
Naimish Patel
SELL
3150 shares
2026-03-16
Samarth Kulkarni
SELL
10349 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 42 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 59 HOLD |
Advanced CRSP Option Strategies
Professional options setups generated by AI based on today's CRSP price and gamma walls.
